Anti-Vascular Endothelial Growth Factor Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Disease, By End Users, By Region and Competition, 2020-2030F

Description

The Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, valued at USD 14.38 Billion in 2024, is projected to experience a CAGR of 3.65% to reach USD 17.83 Billion by 2030. Anti-vascular endothelial growth factor (VEGF) therapeutics are a class of biological drugs designed to inhibit the formation of new blood vessels, a process crucial in the progression of various diseases. These therapies are predominantly utilized in the treatment of ophthalmic conditions, such as age-related macular degeneration and diabetic macular edema, as well as several types of cancer.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 14.38 Billion
Market Size 2030	USD 17.83 Billion
CAGR 2025-2030	3.65%
Fastest Growing Segment	Eylea
Largest Market	North America

Key Market Drivers

The escalating global prevalence of ophthalmic diseases, particularly age-related macular degeneration (AMD) and diabetic macular edema (DME), serves as a substantial impetus for the anti-vascular endothelial growth factor therapeutics market. These debilitating conditions, which are leading causes of blindness and severe vision impairment worldwide, necessitate effective and sustained pharmacological intervention. Enhanced diagnostic capabilities and improved patient access to ophthalmological care contribute to a larger identified patient pool requiring treatment.

Key Market Challenges

The global anti-vascular endothelial growth factor therapeutics market faces a significant challenge from the impending patent expirations of several established biological drugs. This scenario is expected to intensify biosimilar competition, which directly influences the market dynamics for originator manufacturers. As biosimilar versions become available, they enter the market at considerably lower prices to gain market share. This increased competition drives down the average selling prices across the entire product class.

Key Market Trends

The Global Anti-Vascular Endothelial Growth Factor (VEGF) Therapeutics Market is significantly shaped by the expanding market penetration of anti-VEGF biosimilars. This trend is driven by the imperative to enhance cost-effectiveness and broaden patient access to critical therapies, particularly as key originator biologics face patent expirations. Biosimilars introduce robust price competition, thereby fostering greater affordability and increasing the overall volume of anti-VEGF treatments dispensed.

Key Market Players

F. Hoffmann-La Roche Ltd.
Biogen MA Inc.
Pfizer Inc.
Coherus BioSciences, Inc.
Amgen Inc.
Viatris Inc.
Bausch Health Companies Inc.
Novartis AG
Regeneron Pharmaceuticals Inc.

Report Scope:

In this report, the Global Anti-Vascular Endothelial Growth Factor Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anti-Vascular Endothelial Growth Factor Therapeutics Market, By Product:

Eylea
Lucentis
Beovu

Anti-Vascular Endothelial Growth Factor Therapeutics Market, By Disease:

Macular Edema
Diabetic Retinopathy
Retinal Vein Occlusion
Age-related Macular Degeneration

Anti-Vascular Endothelial Growth Factor Therapeutics Market, By End Users:

Hospitals & Clinics
Ambulatory Care centers
Others

Anti-Vascular Endothelial Growth Factor Therapeutics Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Anti-Vascular Endothelial Growth Factor Therapeutics Market.

Available Customizations:

Global Anti-Vascular Endothelial Growth Factor Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Product (Eylea, Lucentis, Beovu)
- 5.2.2. By Disease (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration)
- 5.2.3. By End Users (Hospitals & Clinics, Ambulatory Care centers, Others)
- 5.2.4. By Region
- 5.2.5. By Company (2024)
5.3. Market Map

6. North America Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Product
- 6.2.2. By Disease
- 6.2.3. By End Users
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Product
    - 6.3.1.2.2. By Disease
    - 6.3.1.2.3. By End Users
- 6.3.2. Canada Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Product
    - 6.3.2.2.2. By Disease
    - 6.3.2.2.3. By End Users
- 6.3.3. Mexico Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Product
    - 6.3.3.2.2. By Disease
    - 6.3.3.2.3. By End Users

7. Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Product
- 7.2.2. By Disease
- 7.2.3. By End Users
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Product
    - 7.3.1.2.2. By Disease
    - 7.3.1.2.3. By End Users
- 7.3.2. France Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Product
    - 7.3.2.2.2. By Disease
    - 7.3.2.2.3. By End Users
- 7.3.3. United Kingdom Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Product
    - 7.3.3.2.2. By Disease
    - 7.3.3.2.3. By End Users
- 7.3.4. Italy Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Product
    - 7.3.4.2.2. By Disease
    - 7.3.4.2.3. By End Users
- 7.3.5. Spain Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Product
    - 7.3.5.2.2. By Disease
    - 7.3.5.2.3. By End Users

8. Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Product
- 8.2.2. By Disease
- 8.2.3. By End Users
- 8.2.4. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Product
    - 8.3.1.2.2. By Disease
    - 8.3.1.2.3. By End Users
- 8.3.2. India Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Product
    - 8.3.2.2.2. By Disease
    - 8.3.2.2.3. By End Users
- 8.3.3. Japan Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Product
    - 8.3.3.2.2. By Disease
    - 8.3.3.2.3. By End Users
- 8.3.4. South Korea Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Product
    - 8.3.4.2.2. By Disease
    - 8.3.4.2.3. By End Users
- 8.3.5. Australia Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Product
    - 8.3.5.2.2. By Disease
    - 8.3.5.2.3. By End Users

9. Middle East & Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Product
- 9.2.2. By Disease
- 9.2.3. By End Users
- 9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Product
    - 9.3.1.2.2. By Disease
    - 9.3.1.2.3. By End Users
- 9.3.2. UAE Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Product
    - 9.3.2.2.2. By Disease
    - 9.3.2.2.3. By End Users
- 9.3.3. South Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Product
    - 9.3.3.2.2. By Disease
    - 9.3.3.2.3. By End Users

10. South America Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Product
- 10.2.2. By Disease
- 10.2.3. By End Users
- 10.2.4. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Product
    - 10.3.1.2.2. By Disease
    - 10.3.1.2.3. By End Users
- 10.3.2. Colombia Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Product
    - 10.3.2.2.2. By Disease
    - 10.3.2.2.3. By End Users
- 10.3.3. Argentina Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Product
    - 10.3.3.2.2. By Disease
    - 10.3.3.2.3. By End Users

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. F. Hoffmann-La Roche Ltd.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Biogen MA Inc.
15.3. Pfizer Inc.
15.4. Coherus BioSciences, Inc.
15.5. Amgen Inc.
15.6. Viatris Inc.
15.7. Bausch Health Companies Inc.
15.8. Novartis AG
15.9. Regeneron Pharmaceuticals Inc.